Loading provider…
Loading provider…
Internal Medicine Physician in New York, NY
NPI: 1245524487Primary Employer
Memorial Hematology Lymphoma Group
mskcc.org
HQ Phone
Get M.D., PH.D. Aaron's Phone Numberphone_androidMobile
Get M.D., PH.D. Aaron's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
FL State Medical License
2021
NY State Medical License
2014 - 2026
NJ State Medical License
2018 - 2025
NC State Medical License
2020 - 2022
ME State Medical License
2020 - 2021
MA State Medical License
2014 - 2015

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Weill Cornell Medicine
weill.cornell.edu
Medical School
Until 2011
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
2014 - 2017
Mass General Brigham/Brigham and Women's Hospital
Residency • Internal Medicine
2011 - 2014
Rockefeller University
PhD • Epigenetics and Chromatin Biology
2004 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 104 | 214 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 66 | 98 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 46 | 63 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 41 | 41 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 39 | 275 |
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
Authors: Stahl, Maximilian, Goldberg, Aaron D
Journal: Curr Oncol Rep
Publication Date: 2019-03-23
Lead Sponsor: Aprea Therapeutics
Intervention / Treatment: DRUG: Venetoclax, DRUG: Azacitidine, DRUG: APR-246
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Pfizer
Intervention / Treatment: DRUG: Azacitidine, DRUG: Avelumab
Lead Sponsor: Arog Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Midostaurin, DRUG: Cytarabine, DRUG: Duanorubicin, DRUG: Crenolanib